Atienza D M, Vogel C L, Trock B, Swain S M
Department of Medicine, VA Medical Center, Amarillo, Texas 79106, USA.
Cancer. 1995 Dec 15;76(12):2485-90. doi: 10.1002/1097-0142(19951215)76:12<2485::aid-cncr2820761212>3.0.co;2-j.
The objective of this study was to define the activity and toxicity of etoposide for patients with previously treated metastatic breast cancer.
Thirty patients with measurable metastatic breast cancer who progressed after prior chemotherapy, hormonal therapy, or both, either as adjuvant therapy or for metastatic disease, were enrolled. There were 26 patients evaluable for response and 30 evaluable for toxicity. Treatment consisted of oral etoposide at a dose of 50 mg/m2/day administered for 21 consecutive days. Doses were modified depending on toxicity. Patients were evaluable for response after at least one cycle of therapy.
One complete response and four partial responses were observed. The overall objective response rate was 19% (5/26). Six patients had stable disease. Toxicity consisted mainly of Grade 4 neutropenia for 24% and Grade 4 thrombocytopenia for 13% of patients. There was one death due to neutropenic sepsis.
Oral etoposide is an effective, easily administered outpatient regimen with minimal toxicities. Etoposide is effective for patients with pretreated metastatic breast cancer.
本研究的目的是确定依托泊苷对既往接受过治疗的转移性乳腺癌患者的活性和毒性。
招募了30例可测量的转移性乳腺癌患者，这些患者在先前的化疗、激素治疗或两者联合治疗（作为辅助治疗或转移性疾病治疗）后病情进展。其中26例患者可评估疗效，30例可评估毒性。治疗方案为口服依托泊苷，剂量为50mg/m²/天，连续服用21天。根据毒性调整剂量。患者在至少一个治疗周期后可评估疗效。
观察到1例完全缓解和4例部分缓解。总体客观缓解率为19%（5/26）。6例患者病情稳定。毒性主要包括24%的患者出现4级中性粒细胞减少和13%的患者出现4级血小板减少。有1例患者因中性粒细胞减少性败血症死亡。
口服依托泊苷是一种有效、易于给药的门诊治疗方案，毒性极小。依托泊苷对既往接受过治疗的转移性乳腺癌患者有效。
